| Literature DB >> 36204355 |
Abstract
Background: Pathogen spectrum and antibiotic susceptibility patterns vary in different regions and should consider the empirical treatment of urinary tract infections (UTIs). Information on susceptibility is the basis for providing reliable treatment. This study aimed to determine the antibiotic susceptibility of bacteria isolated from urine cultures at Çukurova State Hospital, which is located south of Turkey and east of the Mediterranean region. Materials and methods: Urine culture results were retrospectively evaluated between April 2018 and January 2021. Variables, such as age, sex, and medical department, were also recorded. Inclusion criteria were patients aged at least 18 years with pathogenic bacterial growth in their urine cultures. Antibiotic susceptibility testing and bacterial identification were performed using the VITEK 2 automated system.Entities:
Keywords: Antibiotics; Antimicrobial susceptibility; Escherichia coli; Urinary tract infections
Year: 2022 PMID: 36204355 PMCID: PMC9527924 DOI: 10.1097/CU9.0000000000000144
Source DB: PubMed Journal: Curr Urol ISSN: 1661-7649
Comparison of patients according to demographic variables.
| n = 1698 | Mean (SD) age, yr |
| |
|---|---|---|---|
| Sex | <0.001* | ||
| Female | 1321 (77.8%) | 53.5 (19.1) | |
| Male | 377 (22.2%) | 62.9 (17.9) | |
| Department | <0.001† | ||
| Outpatient | 1359 (80.0%) | 51.2 (17.7) | |
| Inpatient | 95 (5.6%) | 66.5 (15.3) | |
| Intensive care unit | 244 (14.4%) | 75.4 (19.2) |
Statistically significant differences are observed between sexes and departments in terms of age.
*t test.
†Analysis of variance.
Rate of uropathogens in different department settings.
| Pathogen | Outpatient, % | Inpatient, % | ICU, % | Total, % |
|---|---|---|---|---|
|
| 57.8 | 3.1 | 5.1 | 66 |
| ESBL (−) | 62.7 | 25 | 31.3 | |
| ESBL (+) | 37.3 | 75 | 68.7 | |
| 10 | 0.7 | 3.5 | 14.2 | |
| ESBL (−) | 48.1 | 59 | 42.9 | |
| ESBL (+) | 51.9 | 41 | 57.1 | |
| 2.1 | 0.5 | 1.9 | 4.5 | |
| 2.9 | 0.2 | 0.4 | 3.6 | |
| 1.2 | 0.6 | 1.3 | 3.1 | |
| 2.0 | 0.0 | 0.3 | 2.3 | |
| 1.6 | 0.1 | 0.3 | 2.1 | |
| 1.5 | 0.0 | 0.0 | 1.5 | |
| 0.5 | 0.2 | 0.4 | 1.1 | |
| 0.1 | 0.1 | 0.9 | 1.1 | |
| Others | 0.3 | 0.0 | 0.2 | 0.5 |
| Gram staining | ||||
| Gram (−) | 74.4 | 5.1 | 12.2 | 91.6 |
| Gram (+) | 5.6 | 0.5 | 2.2 | 8.4 |
| Total | 80 | 5.6 | 14.4 | 100 |
ESBL = extended-spectrum β-lactamase; ICU = intensive care unit.
Escherichia coli is the most prevalent bacteria in all department settings.
Rate of uropathogens in different age groups.
| Pathogen | 18–65 yr, % | >65 yr, % | Total, % |
|---|---|---|---|
|
| 47.6 | 18.4 | 66 |
| 7.7 | 6.5 | 14.2 | |
| 2.0 | 2.5 | 4.5 | |
| 2.2 | 1.4 | 3.6 | |
| 1.2 | 1.9 | 3.1 | |
| 1.9 | 0.4 | 2.3 | |
| 1.4 | 0.6 | 2.1 | |
| 1.3 | 0.2 | 1.5 | |
| 0.5 | 0.6 | 1.1 | |
| 0.3 | 0.8 | 1.1 | |
| Others | 0.1 | 0.6 | 0.7 |
| Total | 66.1 | 33.9 | 100 |
Escherichia coli is the most prevalent bacteria in all age groups.
Rate of uropathogens in both sexes.
| Pathogen | Female, % | Male, % | Total, % |
|---|---|---|---|
|
| 55.1 | 10.9 | 66 |
| 10.1 | 4.1 | 14.2 | |
| 2.2 | 2.4 | 4.5 | |
| 2.7 | 0.9 | 3.6 | |
| 1.5 | 1.6 | 3.1 | |
| 1.7 | 0.6 | 2.3 | |
| 1.3 | 0.8 | 2.1 | |
| 1.5 | 0.0 | 1.5 | |
| 0.8 | 0.4 | 1.1 | |
| 0.6 | 0.4 | 1.1 | |
| Others | 0.3 | 0.2 | 0.5 |
| Total | 77.8 | 22.2 | 100 |
Escherichia coli is the most prevalent bacteria in female patients; however, Enterococcus and Pseudomonas species are more common in males than in females.
Antibiotic resistance rates of isolated uropathogens (%).
| Antibiotic | Others, % (n) | Ovarall resistance rate, % (n) | Times studied in susceptibility tests | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amikacin | 27.8 (308) | 39.8 (96) | 59.6 (31) | 47.5 (29) | 26.9 (7) | 7.4 (2) | 11.4 (4) | 0 | 57.9 (11) | 83.3 (15) | 50 (4) | 31.4 (507) | 1617 |
| Amoxicillin | 19.4 (108) | 20 (25) | N/A | 46.9 (15) | 52.2 (12) | 37.5 (3) | 30 (6) | 50 (1) | 85.7 (6) | 100 (10) | 0 | 23.6 (186) | 788 |
| Ampicillin | 60.6 (416) | 94.6 (123) | 15.2 (5) | 57.1 (16) | 71.4 (10) | 55 (11) | 94.1 (16) | N/A | 100 (3) | 100 (4) | 100 (1) | 64.6 (605) | 937 |
| Aztreonam | 11.6 (89) | 23.6 (41) | 0 | 24.4 (10) | 33.3 (3) | 22.2 (2) | 25.9 (7) | 66.7 (2) | 100 (3) | 88.9 (8) | 60 (3) | 16 (168) | 1048 |
| Cefepime | 33.1 (167) | 41 (43) | 0 | 28 (7) | 38.5 (5) | 25 (1) | 27.8 (5) | 0 | N/A | 87.5 (7) | 75 (3) | 34.2 (238) | 696 |
| Cefixime | 20.8 (133) | 30.1 (37) | N/A | 21.4 (6) | 0 | 5.3 (1) | 47.4 (9) | 0 | 66.7 (2) | 100 (3) | 0 | 22.4 (191) | 853 |
| Cefoxitin | 3.9 (18) | 20 (18) | 19.5 (8) | 12.5 (3) | 21.4 (3) | 5.3 (1) | 30 (3) | 0 | 66.7 (4) | 80 (4) | 0 | 9 (62) | 692 |
| Ceftazidime | 17.1 (125) | 26.5 (39) | 8.9 (4) | 7.9 (3) | 31.3 (10) | 14.8 (4) | 9.5 (2) | 84.2 (16) | 62.5 (5) | 72.7 (8) | 40 (2) | 20.1 (218) | 1082 |
| Ceftriaxone | 37.1 (174) | 41.3 (38) | 0 | 31.3 (5) | 100 (11) | 75 (3) | 33.3 (6) | 0 | 100 (3) | 100 (2) | 0 | 38.8 (242) | 624 |
| Cefuroxime axetil | 34.4 (308) | 38.4 (76) | 33.3 (1) | 26 (13) | 34.8 (8) | 22.7 (5) | 23.1 (6) | N/A | 66.7 (4) | 93.3 (14) | 28.6 (2) | 35.1 (437) | 1246 |
| Ciprofloxacin | 36.2 (394) | 41.3 (95) | 54.2 (26) | 38.6 (22) | 38.9 (14) | 33.3 (9) | 20 (7) | N/A | 58.3 (7) | 84.4 (14) | 57.1 (4) | 38 (592) | 1556 |
| Colistin | 46.4 (180) | 62.6 (62) | 0 | 46.7 (14) | 80 (4) | 57.1 (4) | 50 (7) | 33.3 (1) | N/A | 100 (7) | 100 (3) | 50.3 (282) | 561 |
| Ertapenem | 10.4 (75) | 14.8 (21) | 0 | 27.8 (10) | 68.2 (15) | 14.3 (4) | 12 (3) | 5.9 (1) | 72.7 (8) | 71.4 (5) | 100 (3) | 13.9 (145) | 1040 |
| Fosfomycin | 14.6 (140) | 24.8 (50) | 43.8 (14) | 32.1 (17) | 56.3 (9) | 42.9 (15) | 22.2 (6) | 0 | 100 (9) | 92.3 (12) | 80 (4) | 20.4 (276) | 1350 |
| Gentamicin | 17 (93) | 13.2 (14) | 30.8 (4) | 56.5 (13) | 6.7 (1) | 60 (21) | 5.6 (1) | 0 | 33.3 (3) | 100 (7) | 50 (1) | 20.4 (158) | 775 |
| Imipenem | 3.5 (17) | 12.1 (11) | N/A | 47.4 (9) | 18.2 (4) | 63.6 (7) | 0 | N/A | 22.2 (2) | 80 (4) | N/A | 8.2 (54) | 657 |
| Levofloxacin | 25.4 (112) | 45.1 (51) | 12.5 (2) | 41.4 (12) | 66.7 (2) | 50 (5) | 80 (12) | 50 (2) | 100 (1) | 92.3 (12) | 50 (2) | 32.8 (213) | 649 |
| Linezolid | 33.6 (116) | 57.3 (51) | 0 | 28 (7) | 0 | 12.5 (2) | 80 (8) | 20 (1) | N/A | 100 (10) | 25 (1) | 37.9 (196) | 517 |
| Meropenem | 10.5 (71) | 20.5 (26) | N/A | 4.3 (1) | 20 (4) | 9.1 (2) | 31.6 (6) | N/A | 28.6 (2) | 75 (3) | 0 | 12.8 (115) | 897 |
| Netilmicin | 38.5 (177) | 59.1 (68) | 0 | 40 (12) | 38.1 (8) | 25 (1) | 18.8 (3) | 0 | 100 (7) | 92.9 (13) | 50 (3) | 42.5 (292 | 687 |
| Nitrofurantoin | 12.5 (129) | 35.9 (66) | 0 | 66.7 (34) | 50 (13) | 53.6 (15) | 15 (3) | 38.1 (8) | 87.5 (7) | 91.7 (11) | 85.7 (6) | 20.9 (292) | 1400 |
| Piperacillin | 7.2 (42) | 23.9 (34) | 0 | 33.3 (12) | 25 (5) | 42.9 (3) | 0 | 33.3 (1) | 62.5 (5) | 84.6 (11) | 33.3 (2) | 13.5 (115) | 849 |
| Piperacillin-tazobactam | 22.7 (141) | 37 (44) | N/A | 21.4 (6) | 20 (3) | 21.1 (4) | 21.1 (4 | N/A | N/A | 60 (3) | 0 | 24.8 (205) | 828 |
| Teicoplanin | 14.6 (58) | 33.3 (34) | 0 | 19.2 (5) | 44.4 (8) | 37.5 (6) | 6.3 (1) | 16.7 (1) | 100 (6) | 100 (8) | 16.7 (1) | 20.9 (128) | 611 |
| Tigecycline | 42.4 (181) | 63.4 (71) | 0 | 41.4 (12) | 66.7 (2) | 18.2 (2) | 20 (3) | 20 (1) | 100 (1) | 100 (13) | 75 (3) | 45.8 (289) | 631 |
| Tobramycin | 34.6 (176) | 54 (67) | 40 (4) | 35.5 (11) | 22.2 (2) | 27.3 (3) | 50 (8) | 0 | 100 (1) | 100 (8) | 33.3 (1) | 38.8 (282) | 727 |
| TMP-SMX | 37.6 (368) | 62.7 (133) | 37.5 (12) | 36.5 (19) | 53.8 (7) | 20 (2) | 50 (16) | 0 | 50 (6) | 83.3 (10) | 60 (3) | 42.3 (576) | 1363 |
| Vancomycin | 8.9 (39) | 21.6 (24) | 0 | 24.1 (7) | 29.4 (5) | 35.3 (6) | 6.3 (1) | 0 | 33.3 (2) | 91.7 (11) | 33.3 (2) | 14.5 (97) | 667 |
N/A = not assessed; TMP-SMX = trimethoprim-sulfamethoxazole.
All evaluated pathogens and their antibiotic resistance rates.
Percentages represent the resistance rate of the pathogen to related antibiotic. Provided numbers in the parenthesis shows resisted case numbers to related antibiotic. The resistance rate calculated with the formula of [Resisted pathogen cases to related antibiotic / Total pathogen cases that susceptibility test includes related antibiotic].